VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Addressing Challenges With Sedation in End-of-Life Care.
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
GARCIA-MANERO, GUILLERMO
One or more keywords matched the following items that are connected to
GARCIA-MANERO, GUILLERMO
Item Type
Name
Concept
Isocitrate Dehydrogenase
Academic Article
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
Academic Article
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Academic Article
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Academic Article
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission.
Academic Article
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Academic Article
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
Academic Article
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Academic Article
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Academic Article
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Academic Article
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Academic Article
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Academic Article
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Academic Article
A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies.
Academic Article
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Search Criteria
Isocitrate Dehydrogenase